Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4330-4334

  Park, Hwangseo ^a   Bahn, Young Jae ^b   Ryu, Seong Eon ^b  

^a Sejong University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Anticancer agents; Cdc25 phosphatase; De novo design; Docking

Indexed keywords

1 PHENYL 2 (4H [1,2,4]TRIAZOLE 3 YLSULFANYL)ETHANONE; 5 METHYLENE 2 PHENYLAMINO THIAZOL 4 ONE; ANTINEOPLASTIC AGENT; NSC 95397; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; IC 50;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CDC25 PHOSPHATASES; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR CONFORMATION; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67649934675     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.084     Document Type: Article

References (28)

1. Kristjansdottir K., and Rudolph J. Chem. Biol. 11 (2004) 1043
2. Rudolph J. Biochemistry 46 (2007) 3595
3. Galaktionov K., Lee A.K., Eckstein J., Draetta G., Meckler J., Loda M., and Beach D. Science 269 (1995) 1575
4. Takemara I., Yamamoto H., Sekimoto M., Ohue M., Noura S., Miyake Y., Matsumoto T., Aihara T., Tomita N., Tamaki Y., Sakita I., Kikkawa N., Matsuura N., Shiozaki H., and Monden M. Cancer Res. 60 (2000) 3043
5. Ngan E.S.W., Hashimoto Y., Ma Z.-Q., Tsai M.J., and Tsai S.Y. Oncogene 22 (2003) 734
6. Boutros R., Dozier C., and Ducommun B. Curr. Opin. Cell Biol. 18 (2006) 185
7. Fauman E.B., Cogswell J.P., Lovejoy B., Rocque W.J., Holmes W., Montana V.G., Piwnica-Worms H., Rink M.J., and Saper M.A. Cell 93 (1998) 617
8. Reynolds R.A., Yem A.W., Wolfe C.L., Deibel M.R., Chidester C.G., and Watenpaugh K.D. J. Mol. Biol. 293 (1999) 559
9. Contour-Galcéra M.-O., Sidhu A., Prévost G., Bigg D., and Ducommun B. Pharmcol. Ther. 115 (2007) 1
10. Ham S.W., and Carr B.I. Drug Des. Rev. 1 (2004) 123
11. Lazo J.S., Aslan D.C., Southwick E.C., Cooley K.A., Ducruet A.P., Joo B., Vogt A., and Wipf P. J. Med. Chem. 44 (2001) 4042
12. Sohn J., Kiburz B., Li Z., Deng L., Safi A., Pirrung M.C., and Rudolph J. J. Med. Chem. 46 (2003) 2580
13. Brault L., Denancé M., Banaszak E., Maadidi S.E., Battaglia E., Bagrel D., and Samadi M. Eur. J. Med. Chem. 42 (2007) 243
14. Huang W., Li J., Zhang W., Zhou Y., Xie C., Luo Y., Li Y., Wang J., Li J., and Lu W. Bioorg. Med. Chem. Lett. 16 (2006) 1905
15. Lazo J.S., Nemoto K., Pestell K.E., Cooley K., Southwick E.C., Mitchell D.A., Furey W., Gussio R., Zaharevitz D.W., Joo B., and Wipf P. Mol. Pharmacol. 61 (2002) 720
16. Lavecchia A., Cosconati S., Limongelli V., and Novellino E. ChemMedChem 1 (2006) 540
17. Park H., Carr B.I., Li M., and Ham S.W. Bioorg. Med. Chem. Lett. 17 (2007) 2351
18. Park H., Bahn Y.J., Jung S.-K., Jeong D.G., Lee S.-H., Seo I., Yoon T.-S., Kim S.J., and Ryu S.E. J. Med. Chem. 51 (2008) 5533
19. Shoichet B.K., Leach A.R., and Kuntz I.D. Proteins 34 (1999) 4
20. Wang R., Gao Y., and Lai L. J. Mol. Model. 6 (2000) 498
21. Wang R., Liu L., and Lai L. J. Mol. Model. 6 (1998) 379
22. Gasteiger J., and Marsili M. Tetrahedron 36 (1980) 3219
23. Kang H., Choi H., and Park H. J. Chem. Inf. Model. 47 (2007) 509
24. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. J. Comput. Chem. 19 (1998) 1639
25. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 23 (1997) 3
26. With respect to the numbering scheme for the amino acids, we followed those used in the X-ray crystallographic studies of Cdc25A (Ref. 7) and Cdc25B (Ref. 8).
27. Tamura K., Southwick E.C., Kerns J., Rosi K., Carr B.I., Wilcox C., and Lazo J.S. Cancer Res. 60 (2000) 1317
28. Osada S., Osada K., and Carr B.I. J. Mol. Biol. 314 (2001) 765